MedTrace Logo

Hyaluronic Acid for Soft Tissue Injuries

NCT05278897 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-03-14

No results posted yet for this study

Summary

Soft Tissue Adapted Biocompatible Hyaluronic Acid, or STABHA™, has demonstrated varying degrees efficacy in patients treated for common musculoskeletal tendinopathies and ligament injuries, such as ankle sprains, lateral elbow tendinopathy, and rotator cuff tendinopathies. Factors associated with prognosis following treatment remain largely unknown. Identifying appropriate patient populations for use of STABHA™ is a necessary first step to facilitate the design of future clinical trials in the management of acute and chronic musculoskeletal soft-tissue injuries.

Conditions

  • Elbow Tendinopathy
  • Ankle Sprains

Interventions

DEVICE

Soft Tissue Adapted Biocompatible Hyaluronic Acid

1% sodium hyaluronate

Sponsors & Collaborators

  • Pendopharm

    collaborator INDUSTRY

  • Global Research Solutions

    lead INDUSTRY

Principal Investigators

  • Mohit Bhandari · Global Research Solutions

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2024-05-13
Completion
2024-05-13

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05278897 on ClinicalTrials.gov